Actinium Pharmaceuticals, Inc. (ATNM) is a biopharmaceutical company with a proprietary platform that uses large molecules that bind to specific cancer cell types and affixed radioisotopes in order to deliver targeted decimation to cancer cells. Utilizing this platform the company is focused on developing innovative alpha particle immunotherapeutics for the therapeutic utilization of alpha particle emitting radiopharmaceuticals in association with monoclonal antibodies.